Lancet Respir Med:COPD患者心血管并发症风险的研究

2015-07-26 MedSci MedSci原创

    慢性阻塞性肺疾病(COPD)是一种全身性炎症性疾病,并增加了患者心血管疾病的风险。该研究的目的是量化心血管疾病,心血管疾病的主要危险因素,以及COPD整体和特定类型之间的关联程度。    研究人员检索了Cochrane,MEDLINE和Embase数据库在1980年1月1日和2015年4月30日间发表的研究报告,对心血管疾病的患病率和COPD患者与匹

慢性阻塞性肺疾病(COPD)是一种全身性炎症性疾病,并增加了患者心血管疾病的风险。该研究的目的是量化心血管疾病,心血管疾病的主要危险因素,以及COPD整体和特定类型之间的关联程度。

研究人员检索了Cochrane,MEDLINE和Embase数据库在1980年1月1日和2015年4月30日间发表的研究报告,对心血管疾病的患病率和COPD患者与匹配的对照或一般市民随机样本及其危险因素。研究人员评估了随机效应荟萃分析。研究人员通过随机效应荟萃回归, jackknife 敏感性分析,漏斗图评估,以及Egger测试研究了异质性和偏差。

研究人员确定了18176个独特的参考文献,荟萃分析中包括29个数据集。与非COPD人群相比,COPD患者更有可能被诊断为心血管疾病(比值比[OR]2.46;95%Cl 2.02-3.00,P<0.0001),其中包括2至5倍风险的缺血性心脏疾病,心律不整,心脏衰竭,肺循环疾病,和动脉疾病。此外,COPD患者被报道的高血压(OR 1.33,95%Cl 1.13-1.56,P=0.0007),糖尿病(1.36,1.21-1.53,P <0.0001],和曾经吸烟(4.25,3.23-5.60,P<0.0001)现象更常见。在整个研究期间COPD与这些心血管疾病的类型和心血管疾病的危险因素之间的关联是一致的和有效的。招募时间,年龄,数据的质量,和COPD的诊断部分解释了异质性。

COPD,心血管疾病,心血管疾病的主要危险因素的并存强调了对筛查策略的迫切需要,来减少与COPD相关的心血管风险。

原始出处:

Dr Wenjia Chen, MPHcorrespondence†email, Jamie Thomas, BSc†, Mohsen Sadatsafavi, PhD, J Mark FitzGerald, MD,Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease,Lancet Respiratory Medicine,2015.7.21

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828184, encodeId=3a88182818400, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 16 18:43:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38555, encodeId=3f993855503, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38556, encodeId=e6d038556d4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757662, encodeId=88b81e57662dd, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Aug 01 12:43:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35114, encodeId=8371351143b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488776, encodeId=69511488e76be, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515100, encodeId=b3fb151510065, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545335, encodeId=89a015453359e, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606554, encodeId=539d160655498, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33526, encodeId=8c123352640, content=这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jul 26 19:28:00 CST 2015, time=2015-07-26, status=1, ipAttribution=)]
    2015-08-16 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828184, encodeId=3a88182818400, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 16 18:43:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38555, encodeId=3f993855503, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38556, encodeId=e6d038556d4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757662, encodeId=88b81e57662dd, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Aug 01 12:43:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35114, encodeId=8371351143b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488776, encodeId=69511488e76be, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515100, encodeId=b3fb151510065, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545335, encodeId=89a015453359e, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606554, encodeId=539d160655498, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33526, encodeId=8c123352640, content=这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jul 26 19:28:00 CST 2015, time=2015-07-26, status=1, ipAttribution=)]
    2015-10-12 hlycom3356

    这篇文章写的很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1828184, encodeId=3a88182818400, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 16 18:43:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38555, encodeId=3f993855503, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38556, encodeId=e6d038556d4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757662, encodeId=88b81e57662dd, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Aug 01 12:43:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35114, encodeId=8371351143b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488776, encodeId=69511488e76be, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515100, encodeId=b3fb151510065, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545335, encodeId=89a015453359e, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606554, encodeId=539d160655498, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33526, encodeId=8c123352640, content=这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jul 26 19:28:00 CST 2015, time=2015-07-26, status=1, ipAttribution=)]
    2015-10-12 hlycom3356

    这篇文章写的很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1828184, encodeId=3a88182818400, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 16 18:43:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38555, encodeId=3f993855503, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38556, encodeId=e6d038556d4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757662, encodeId=88b81e57662dd, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Aug 01 12:43:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35114, encodeId=8371351143b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488776, encodeId=69511488e76be, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515100, encodeId=b3fb151510065, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545335, encodeId=89a015453359e, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606554, encodeId=539d160655498, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33526, encodeId=8c123352640, content=这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jul 26 19:28:00 CST 2015, time=2015-07-26, status=1, ipAttribution=)]
    2015-08-01 丁鹏鹏
  5. [GetPortalCommentsPageByObjectIdResponse(id=1828184, encodeId=3a88182818400, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 16 18:43:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38555, encodeId=3f993855503, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38556, encodeId=e6d038556d4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757662, encodeId=88b81e57662dd, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Aug 01 12:43:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35114, encodeId=8371351143b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488776, encodeId=69511488e76be, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515100, encodeId=b3fb151510065, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545335, encodeId=89a015453359e, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606554, encodeId=539d160655498, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33526, encodeId=8c123352640, content=这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jul 26 19:28:00 CST 2015, time=2015-07-26, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    期待有更多研究

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1828184, encodeId=3a88182818400, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 16 18:43:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38555, encodeId=3f993855503, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38556, encodeId=e6d038556d4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757662, encodeId=88b81e57662dd, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Aug 01 12:43:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35114, encodeId=8371351143b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488776, encodeId=69511488e76be, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515100, encodeId=b3fb151510065, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545335, encodeId=89a015453359e, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606554, encodeId=539d160655498, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33526, encodeId=8c123352640, content=这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jul 26 19:28:00 CST 2015, time=2015-07-26, status=1, ipAttribution=)]
    2015-07-28 gous
  7. [GetPortalCommentsPageByObjectIdResponse(id=1828184, encodeId=3a88182818400, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 16 18:43:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38555, encodeId=3f993855503, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38556, encodeId=e6d038556d4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757662, encodeId=88b81e57662dd, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Aug 01 12:43:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35114, encodeId=8371351143b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488776, encodeId=69511488e76be, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515100, encodeId=b3fb151510065, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545335, encodeId=89a015453359e, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606554, encodeId=539d160655498, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33526, encodeId=8c123352640, content=这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jul 26 19:28:00 CST 2015, time=2015-07-26, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1828184, encodeId=3a88182818400, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 16 18:43:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38555, encodeId=3f993855503, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38556, encodeId=e6d038556d4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757662, encodeId=88b81e57662dd, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Aug 01 12:43:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35114, encodeId=8371351143b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488776, encodeId=69511488e76be, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515100, encodeId=b3fb151510065, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545335, encodeId=89a015453359e, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606554, encodeId=539d160655498, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33526, encodeId=8c123352640, content=这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jul 26 19:28:00 CST 2015, time=2015-07-26, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1828184, encodeId=3a88182818400, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 16 18:43:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38555, encodeId=3f993855503, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38556, encodeId=e6d038556d4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757662, encodeId=88b81e57662dd, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Aug 01 12:43:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35114, encodeId=8371351143b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488776, encodeId=69511488e76be, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515100, encodeId=b3fb151510065, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545335, encodeId=89a015453359e, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606554, encodeId=539d160655498, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33526, encodeId=8c123352640, content=这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jul 26 19:28:00 CST 2015, time=2015-07-26, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1828184, encodeId=3a88182818400, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 16 18:43:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38555, encodeId=3f993855503, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38556, encodeId=e6d038556d4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:24:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757662, encodeId=88b81e57662dd, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Aug 01 12:43:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35114, encodeId=8371351143b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488776, encodeId=69511488e76be, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515100, encodeId=b3fb151510065, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545335, encodeId=89a015453359e, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606554, encodeId=539d160655498, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 08:43:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33526, encodeId=8c123352640, content=这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jul 26 19:28:00 CST 2015, time=2015-07-26, status=1, ipAttribution=)]
    2015-07-26 lovetcm

    这是柳叶刀旗下的一个新的子刊,大家一定要关注哦。

    0

相关资讯

NEJM:撤退吸入糖皮质激素对慢性阻塞性肺疾病(COPD)频繁发作没有显著影响

长效支气管扩张剂联合应用糖皮质激素吸入被推荐用于重度慢性阻塞性肺疾病(COPD)的频繁发作。然而,在吸入糖皮质激素基础上,增加两种长效支气管扩张剂的益处还未得到验证。 最新一项新英格兰期刊上发表了最新研究成果,称为WISDOM 试验,这是一项为期12个月双盲,平行对照试验,共招募2485位慢性COPD急性发作史患者,接收三联治疗,包括tiotropium(噻托溴铵)(18 μg,每天一次

Psychoneuroendocr:临床早期诊断COPD患者抑郁的简便方法:检测促炎性因子和皮质醇水平

在全球范围内,COPD是导致慢性发病率和死亡率的主要原因。在中国,超过4千万人患有COPD,每年的死亡率超过128万。抑郁在COPD患者中十分常见,其会加速疾病的恶化和增加治疗费用。研究发现,抑郁与HPA轴的功能紊乱和促炎性因子有关。而COPD是以系统性炎症反应为特征的疾病,患者的促炎性因子(如IL-1、IL-6和TNF-α)水平升高,而且这些炎性因子会激活HPA轴。然而,关于COPD患者的抑郁与

Thorax:慢性阻塞性肺病患者健康状况变化和随访结果

在COPD患者中,不良的健康状况与发病率和死亡率具有相关性。到目前为止,健康状况的改变对COPD患者的影响还不是很明确。本研究旨在探讨健康状况的相关临床变化与COPD患者病情加重、住院或死亡之间的联系。 本研究共纳入2138名COPD患者,通过健康状况(圣乔治呼吸问卷,SGRQ)评分来评估COPD患者在超过3年时间里慢性阻塞性肺病在ECLIPSE研究中的纵向识别替代终点。使用KM曲线和log-r

J Intern Med:瑞舒伐他汀治疗慢性阻塞性肺疾病COPD的研究

本研究的旨在研究是否可以通过他汀类药物增强内皮依赖性的血管功能来改善COPD患者的肺功能,减少系统性炎症。 研究人员在挪威两所大学对COPD患者进行了一项随机、安慰剂对照、双盲、平行试验。将在稳定期的慢性阻塞性肺病COPD患者(n = 99)随机分配:接受每日一次共12周的10mg瑞舒伐他汀组(n=49)或与之相匹配的安慰剂组(n=50)。主要结局是使用外周动脉张力测定法和表达为反应性充血指数来

NEJM:COPD患者一生中FEV1下降的速度变化很大

OPD患者一生中FEV1下降的速度变化很大1.公认的COPD的致病机制为易感人群第1秒用力呼气容积(FEV1)的加速下降。2.本次大型队列研究中,随访结束后一半的患者确诊为COPD,从成年早期最大的肺功能低开始,遵循了FEV1下降的正常的过程,揭示了COPD发病机制的另一种范式。 慢性阻塞性肺病(COPD)基本病理生理的经典范式为FEV1随时间的推移逐渐下降;这是由于许多人暴露于颗粒物,尤其是烟草

Lancet Respir Med:β2受体激动剂引起的支气管收缩效应

2014年11月的 Lancet Respir Med.杂志中,一篇文章介绍了COPD患者对支气管扩张治疗的反应。研究者设计了一项实验来评估现在吸烟或既往吸烟的COPD和非COPD患者对β2受体激动剂的治疗反应,以及影像学改变与临床症状间的相关性。其结果为,β2受体激动剂的反常反应与呼吸道疾病的发病率相关,且在非裔美国人中更为常见。因此这部分COPD患者应慎用β2受体激动剂。 背景